Baird 'Incrementally Positive' on Sarepta (SRPT) Following 'Shocking Move' by FDA

Baird analyst Brian Skorney is incrementally positive on the FDA's move to include voting questions on Sarepta Therapeutic (NASDAQ: SRPT) eteplirsen.

The analyst called it a "shocking move.

"The final question will gauge panelists' read on the efficacy of the drug," he notes. "This leaves the door open for patient advocates to sway the panel on a definitive vote. Prepare for a wild ride. After years of ambiguity surrounding this review, we head into Monday expecting nothing more than to be surprised."

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $11.02 yesterday.

You May Also Be Interested In

• Fed's Williams: sees steady trend like growth for U.S. economy - Fox Business
• StepStone Group (STEP) Mentioned as short at Bear Cave
• Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®